analyst
RN
NASDAQ · RNA
Avidity Biosciences, Inc.
Healthcare · Biotechnology
$10.09
Down-$0.12 (-1.18%)
Updated Sep 16, 2026, 6:52 AM
SID Score
4.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 9.4B
- P/E ratio
- -20.36
- Dividend yield
- 0.00%
- 52-week range
- $10.00 – $73.06
- Volume
- 274.58K
- Avg. volume
- 5.22M
Price performance
RNA price history
1M range · 20 trading sessions · Daily adjusted prices
RNA closed at $10.09 after 20 trading sessions, down 21.42% for the selected period.
- Last close
- $10.09
- Period change
- -21.42%
- Period low
- $10.09
- Period high
- $14.60
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $10.21 | $10.21 | $9.62 | $10.09 | 274.58K |
| Sep 14, 2026 | $10.37 | $10.71 | $10.15 | $10.21 | 255.71K |
| Sep 11, 2026 | $10.37 | $10.41 | $10.0041 | $10.36 | 247.5K |
| Sep 10, 2026 | $10.44 | $10.74 | $10.28 | $10.35 | 421.63K |
| Sep 9, 2026 | $11.20 | $11.20 | $10.34 | $10.51 | 690.44K |
| Sep 8, 2026 | $14.08 | $14.19 | $10.75 | $11.35 | 1.72M |
| Sep 4, 2026 | $14.51 | $14.65 | $14.01 | $14.19 | 167.79K |
| Sep 3, 2026 | $14.19 | $14.68 | $13.99 | $14.60 | 164.91K |
| Sep 2, 2026 | $13.77 | $14.098 | $13.76 | $14.06 | 111.64K |
| Sep 1, 2026 | $13.24 | $13.92 | $13.20 | $13.77 | 178.71K |
| Aug 31, 2026 | $13.53 | $13.55 | $13.10 | $13.32 | 97.05K |
| Aug 28, 2026 | $13.87 | $13.9508 | $13.51 | $13.64 | 108.64K |
| Aug 27, 2026 | $13.78 | $14.09 | $13.5916 | $13.98 | 120.56K |
| Aug 26, 2026 | $13.93 | $14.07 | $13.66 | $13.85 | 179.35K |
| Aug 25, 2026 | $13.72 | $14.05 | $13.41 | $14.00 | 166.58K |
| Aug 24, 2026 | $13.27 | $13.635 | $13.04 | $13.62 | 140.56K |
| Aug 21, 2026 | $13.53 | $13.59 | $12.96 | $13.20 | 180.68K |
| Aug 20, 2026 | $13.75 | $13.875 | $13.20 | $13.48 | 218.81K |
| Aug 19, 2026 | $13.00 | $13.72 | $12.85 | $13.71 | 360.32K |
| Aug 18, 2026 | $12.91 | $12.96 | $12.72 | $12.84 | 107.92K |
Latest RNA news
The latest Smart Investors Daily articles mentioning RNA.
Stock researchCompany · Overview
RNA research
Overview
Company profile and research snapshot.
Company profile
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $74.44
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 18, 2026 | Cantor Fitzgerald | Overweight | — |
| May 15, 2026 | Leerink Partners | Outperform | — |
| Mar 11, 2026 | Wells Fargo | Overweight | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.